ProShare Advisors LLC Sells 2,030 Shares of Morphic Holding, Inc. (NASDAQ:MORF)

ProShare Advisors LLC reduced its holdings in shares of Morphic Holding, Inc. (NASDAQ:MORFGet Rating) by 20.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,801 shares of the company’s stock after selling 2,030 shares during the quarter. ProShare Advisors LLC’s holdings in Morphic were worth $313,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Point72 Hong Kong Ltd lifted its holdings in Morphic by 983.3% during the fourth quarter. Point72 Hong Kong Ltd now owns 715 shares of the company’s stock worth $34,000 after acquiring an additional 649 shares during the period. Virtus ETF Advisers LLC lifted its holdings in Morphic by 12.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,693 shares of the company’s stock worth $175,000 after acquiring an additional 420 shares during the period. Qube Research & Technologies Ltd bought a new stake in Morphic during the first quarter worth $200,000. PDT Partners LLC bought a new stake in Morphic during the fourth quarter worth $247,000. Finally, OLD Mission Capital LLC bought a new stake in Morphic during the fourth quarter worth $296,000. 81.64% of the stock is currently owned by institutional investors.

Morphic Stock Down 2.3 %

Morphic stock opened at $28.33 on Tuesday. Morphic Holding, Inc. has a 52 week low of $19.23 and a 52 week high of $68.75. The business has a 50-day simple moving average of $26.94 and a 200 day simple moving average of $30.89. The stock has a market cap of $1.09 billion, a price-to-earnings ratio of -19.81 and a beta of 1.46.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on MORF. Royal Bank of Canada dropped their price target on Morphic from $76.00 to $70.00 and set an “outperform” rating on the stock in a report on Thursday, August 4th. BMO Capital Markets restated a “buy” rating and issued a $83.00 target price on shares of Morphic in a research note on Friday, August 5th. Wells Fargo & Company lowered their target price on Morphic from $79.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, August 4th. Finally, SVB Leerink initiated coverage on Morphic in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $45.00 target price on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Morphic presently has an average rating of “Buy” and a consensus target price of $67.83.

Morphic Profile

(Get Rating)

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.

Featured Articles

Want to see what other hedge funds are holding MORF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Morphic Holding, Inc. (NASDAQ:MORFGet Rating).

Institutional Ownership by Quarter for Morphic (NASDAQ:MORF)

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.

ProShare Advisors LLC Sells 2,030 Shares of Morphic Holding, Inc. (NASDAQ:MORF)

ProShare Advisors LLC reduced its holdings in shares of Morphic Holding, Inc. (NASDAQ:MORFGet Rating) by 20.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 7,801 shares of the company’s stock after selling 2,030 shares during the quarter. ProShare Advisors LLC’s holdings in Morphic were worth $313,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Point72 Hong Kong Ltd lifted its holdings in Morphic by 983.3% during the fourth quarter. Point72 Hong Kong Ltd now owns 715 shares of the company’s stock worth $34,000 after acquiring an additional 649 shares during the period. Virtus ETF Advisers LLC lifted its holdings in Morphic by 12.8% during the fourth quarter. Virtus ETF Advisers LLC now owns 3,693 shares of the company’s stock worth $175,000 after acquiring an additional 420 shares during the period. Qube Research & Technologies Ltd bought a new stake in shares of Morphic in the first quarter valued at $200,000. PDT Partners LLC bought a new stake in shares of Morphic in the fourth quarter valued at $247,000. Finally, OLD Mission Capital LLC bought a new stake in shares of Morphic in the fourth quarter valued at $296,000. 81.64% of the stock is currently owned by institutional investors.

Morphic Stock Performance

Shares of NASDAQ MORF opened at $28.33 on Tuesday. The stock has a market cap of $1.09 billion, a PE ratio of -19.81 and a beta of 1.46. Morphic Holding, Inc. has a fifty-two week low of $19.23 and a fifty-two week high of $68.75. The stock has a fifty day moving average of $26.94 and a 200-day moving average of $30.89.

Wall Street Analyst Weigh In

MORF has been the topic of several research reports. SVB Leerink initiated coverage on Morphic in a research note on Wednesday, July 20th. They issued an “outperform” rating and a $45.00 target price on the stock. BMO Capital Markets restated a “buy” rating and issued a $83.00 target price on shares of Morphic in a research note on Friday, August 5th. Wells Fargo & Company lowered their target price on Morphic from $79.00 to $77.00 and set an “overweight” rating on the stock in a research note on Thursday, August 4th. Finally, Royal Bank of Canada lowered their target price on Morphic from $76.00 to $70.00 and set an “outperform” rating on the stock in a research note on Thursday, August 4th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Morphic presently has an average rating of “Buy” and a consensus target price of $67.83.

Morphic Profile

(Get Rating)

Morphic Holding, Inc, a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.

Featured Articles

Want to see what other hedge funds are holding MORF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Morphic Holding, Inc. (NASDAQ:MORFGet Rating).

Institutional Ownership by Quarter for Morphic (NASDAQ:MORF)

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.